Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alamar Biosciences, Inc.ALMR · Entity 1791 | Chief Financial Officer | April 16, 2026 | April 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alamar Biosciences, Inc.
Report date April 16, 2026 · Filed April 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 37,220 |
Reported balance
After 2026-04-20 transaction · row 1
1 source rowRow 1 · 2026-04-20 · Grant · Acquired 37,220 · Balance 37,220 F1: Represents the grant of restricted stock units ("RSUs"). The RSUs vest monthly from the date of grant, subject to the reporting person's continuous service as of each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2036-04-15 | Direct | 163,358 |
Reported balance
After 2026-04-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-16 · Grant · Acquired 163,358 · Balance 163,358 F2: Twenty-five percent of the shares subject to the option vest on April 16, 2027, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service as of each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.62 · Expires 2035-10-14 | Direct | 0 |
Reported balance
After 2026-04-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-20 · Other · Disposed 570,719 · Balance 0 F3: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. F4: Twenty-five percent of the shares subject to the option vest on October 13, 2026, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service through each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.62 · Expires 2035-10-14 | Direct | 570,719 |
Reported balance
After 2026-04-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-04-20 · Other · Acquired 570,719 · Balance 570,719 F3: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. F4: Twenty-five percent of the shares subject to the option vest on October 13, 2026, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units ("RSUs"). The RSUs vest monthly from the date of grant, subject to the reporting person's continuous service as of each such vesting date.
F2: Twenty-five percent of the shares subject to the option vest on April 16, 2027, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service as of each such vesting date.
F3: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock.
F4: Twenty-five percent of the shares subject to the option vest on October 13, 2026, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service through each such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
10x Genomics, Inc.
Report date August 22, 2024 · Filed August 26, 2024
Section 16 reporting ended · disclosed 2024-08-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 143,242 |
Reported balance
After 2024-08-22 transaction · row 1
1 source rowRow 1 · 2024-08-22 · Sale · Disposed 2,961 · Balance 143,242 F1: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 20, 2026 Filed Apr 21, 2026 00:33 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | OtherStock Option (Right to Buy) · Derivative | 570,719 | $0.00 Strike: $4.62 | $0.00 |
DisclosureSEC source: 0001786386-26-000006 · form4-04212026_120457.xml · derivative · entry 4 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 570,719 Underlying: Common Stock · 570,719 shares Expires 2035-10-14 F3 · kind: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. F4 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vest on October 13, 2026, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service through each such vesting date. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:33 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | OtherStock Option (Right to Buy) · Derivative | 570,719 | $0.00 Strike: $4.62 | $0.00 |
DisclosureSEC source: 0001786386-26-000006 · form4-04212026_120457.xml · derivative · entry 3 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 570,719 shares Expires 2035-10-14 F3 · kind: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. F4 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vest on October 13, 2026, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service through each such vesting date. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:33 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | GrantCommon Stock | 37,220 | $0.00 | $0.00 |
DisclosureSEC source: 0001786386-26-000006 · form4-04212026_120457.xml · nonDerivative · entry 1 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,220 F1 · kind: Represents the grant of restricted stock units ("RSUs"). The RSUs vest monthly from the date of grant, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
| April 16, 2026 Filed Apr 21, 2026 00:33 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | GrantStock Option (Right to Buy) · Derivative | 163,358 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001786386-26-000006 · form4-04212026_120457.xml · derivative · entry 2 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 163,358 Underlying: Common Stock · 163,358 shares Expires 2036-04-15 F2 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vest on April 16, 2027, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
| August 22, 2024 Filed Aug 26, 2024 21:03 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,961 | $22.53 | $66,710.44 |
DisclosureSEC source: 0001610717-24-000453 · form4.xml · nonDerivative · entry 1 McAnear Justin J. · CIK 0001786386 · Former Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,242 F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| May 22, 2024 Filed May 23, 2024 23:54 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,936 | $24.30 | $71,355.37 |
DisclosureSEC source: 0001610717-24-000259 · form4.xml · nonDerivative · entry 1 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,203 F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · balance_after: Includes 587 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 14, 2024. Read SEC document |
| March 21, 2024 Filed Mar 25, 2024 21:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantClass A Common Stock | 53,312 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000184 · form4.xml · nonDerivative · entry 1 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,552 F1 · shares: Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/16th of the RSUs shall vest on each quarterly anniversary measured from February 21, 2024, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 21:12 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,865 | $46.34 | $86,432.12 |
DisclosureSEC source: 0001610717-24-000090 · form4.xml · nonDerivative · entry 1 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,240 F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| November 22, 2023 Filed Nov 27, 2023 23:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,679 | $43.34 | $72,762.32 |
DisclosureSEC source: 0001610717-23-000365 · form4.xml · nonDerivative · entry 1 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,105 F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| August 22, 2023 Filed Aug 24, 2023 21:09 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,678 | $45.78 | $76,820.69 |
DisclosureSEC source: 0001610717-23-000237 · form4.xml · nonDerivative · entry 1 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,784 F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| May 23, 2023 Filed May 25, 2023 21:48 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 565 | $55.06 | $31,110.99 |
DisclosureSEC source: 0001610717-23-000064 · form4.xml · nonDerivative · entry 4 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,462 F1 · shares: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| May 23, 2023 Filed May 25, 2023 21:48 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 441 | $55.06 | $24,283.27 |
DisclosureSEC source: 0001610717-23-000064 · form4.xml · nonDerivative · entry 3 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,027 F1 · shares: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| May 23, 2023 Filed May 25, 2023 21:48 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 465 | $55.06 | $25,603.88 |
DisclosureSEC source: 0001610717-23-000064 · form4.xml · nonDerivative · entry 2 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,468 F1 · shares: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| May 23, 2023 Filed May 25, 2023 21:48 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 194 | $55.07 | $10,683.48 |
DisclosureSEC source: 0001610717-23-000064 · form4.xml · nonDerivative · entry 1 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,933 F1 · shares: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · balance_after: Includes 617 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 12, 2023. Read SEC document |
| March 21, 2023 Filed Mar 23, 2023 22:25 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantPerformance based Restricted Stock Units · Derivative | 12,996 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-013504 · form4.xml · derivative · entry 3 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,996 Underlying: Class A Common Stock · 12,996 shares Expires 2028-04-01 F3 · derivative.exercise_price: Each Performance-Based Restricted Stock Unit ("PSU") represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/3rd of the PSUs shall vest upon the Issuer's Class A Common Stock achieving each of three escalating stock price milestones, subject to the Reporting Person continuing as a service provider through each such date. F3 · derivative.exercise_date: Each Performance-Based Restricted Stock Unit ("PSU") represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/3rd of the PSUs shall vest upon the Issuer's Class A Common Stock achieving each of three escalating stock price milestones, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| March 21, 2023 Filed Mar 23, 2023 22:25 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantStock Option (right to buy) · Derivative | 25,991 | $0.00 Strike: $50.10 | $0.00 |
DisclosureSEC source: 0001140361-23-013504 · form4.xml · derivative · entry 2 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,991 Underlying: Class A Common Stock · 25,991 shares Expires 2033-03-21 F2 · derivative.exercise_date: 1/48th of the total number of shares subject to the option vest on each monthly anniversary measured from April 1, 2023, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| March 21, 2023 Filed Mar 23, 2023 22:25 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantClass A Common Stock | 25,991 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-013504 · form4.xml · nonDerivative · entry 1 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,510 F1 · shares: Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/16th of the RSUs shall vest on each quarterly anniversary measured from February 21, 2023, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 22:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,245 | $47.75 | $59,452.86 |
DisclosureSEC source: 0001567619-23-003782 · doc1.xml · nonDerivative · entry 1 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,519 F1 · shares: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| November 22, 2022 Filed Nov 23, 2022 22:02 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 288 | $34.07 | $9,811.15 |
DisclosureSEC source: 0001567619-22-020869 · doc1.xml · nonDerivative · entry 3 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,764 F1 · shares: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| November 22, 2022 Filed Nov 23, 2022 22:02 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 652 | $34.07 | $22,212.27 |
DisclosureSEC source: 0001567619-22-020869 · doc1.xml · nonDerivative · entry 2 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,052 F1 · shares: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| November 22, 2022 Filed Nov 23, 2022 22:02 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 686 | $34.07 | $23,368.66 |
DisclosureSEC source: 0001567619-22-020869 · doc1.xml · nonDerivative · entry 1 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,704 F1 · shares: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · balance_after: Includes 1 share acquired pursuant to the Issuer's Employee Stock Purchase Plan on November 14, 2022. Read SEC document |
| September 14, 2022 Filed Sep 16, 2022 21:34 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantPerformance-based Restricted Stock Units · Derivative | 40,593 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-017565 · doc1.xml · derivative · entry 3 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,593 Underlying: Class A Common Stock · 40,593 shares Expires 2026-09-14 F3 · derivative.exercise_price: Each Performance-Based Restricted Stock Unit ("PSU") represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/3rd of the PSUs vest upon the Issuer's Class A Common Stock achieving each of three escalating stock price milestones, subject to the Reporting Person continuing as a service provider through each such date. F3 · derivative.exercise_date: Each Performance-Based Restricted Stock Unit ("PSU") represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/3rd of the PSUs vest upon the Issuer's Class A Common Stock achieving each of three escalating stock price milestones, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| September 14, 2022 Filed Sep 16, 2022 21:34 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantStock Option (right to buy) · Derivative | 40,593 | $0.00 Strike: $33.67 | $0.00 |
DisclosureSEC source: 0001567619-22-017565 · doc1.xml · derivative · entry 2 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,593 Underlying: Class A Common Stock · 40,593 shares Expires 2032-09-14 F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from September 14, 2022, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| September 14, 2022 Filed Sep 16, 2022 21:34 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantClass A Common Stock | 20,297 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-017565 · doc1.xml · nonDerivative · entry 1 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,389 F1 · shares: Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/16th of the RSUs vest on each quarterly anniversary measured from August 21, 2022, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| August 23, 2022 Filed Aug 25, 2022 20:59 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 987 | $35.19 | $34,733.81 |
DisclosureSEC source: 0001567619-22-016677 · doc1.xml · nonDerivative · entry 1 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,092 F1 · shares: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| May 23, 2022 Filed May 25, 2022 22:32 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 967 | $48.76 | $47,154.88 |
DisclosureSEC source: 0001567619-22-011713 · doc1.xml · nonDerivative · entry 1 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,079 F1 · shares: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| May 13, 2022 Filed May 17, 2022 21:28 UTC | 10x Genomics, Inc. TXG · Entity 2172 | PurchaseClass A Common Stock | 158 | $40.49 | $6,396.71 |
DisclosureSEC source: 0001567619-22-011123 · doc1.xml · nonDerivative · entry 1 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,046 F1 · kind: The purchase was made under the Issuer's 2019 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) under Rule 16b-3(c). Read SEC document |
| March 22, 2022 Filed Mar 24, 2022 21:14 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantStock Option (Right to Buy) · Derivative | 53,392 | $0.00 Strike: $69.56 | $0.00 |
DisclosureSEC source: 0001567619-22-007440 · doc1.xml · derivative · entry 2 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,392 Underlying: Class A Common Stock · 53,392 shares Expires 2032-03-22 F2 · derivative.exercise_date: This option, granted pursuant to the Issuer's 2019 Omnibus Incentive Plan, vests as to one forty-eighth of the shares on May 1, 2022 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| March 22, 2022 Filed Mar 24, 2022 21:14 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantClass A Common Stock | 21,357 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-007440 · doc1.xml · nonDerivative · entry 1 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,888 F1 · shares: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock. One-sixteenth of the RSUs shall vest on May 21, 2022 and on each three-month anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 00:38 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 288 | $78.60 | $22,636.63 |
DisclosureSEC source: 0001567619-22-005520 · doc1.xml · nonDerivative · entry 1 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,531 F1 · shares: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 22:16 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001567619-22-000622 · doc1.xml · derivative · entry 7 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,159 Underlying: Class A Common Stock · 10,000 shares Expires 2028-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F7 · derivative.exercise_date: This option, originally for 600,000 shares, of which 249,841 shares have been exercised, vested as to 1/4th of the shares on October 8, 2019 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 22:16 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 500 | $149.18 | $74,589.00 |
DisclosureSEC source: 0001567619-22-000622 · doc1.xml · nonDerivative · entry 6 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,819 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $148.66 to $149.55. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 22:16 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 500 | $148.04 | $74,022.00 |
DisclosureSEC source: 0001567619-22-000622 · doc1.xml · nonDerivative · entry 5 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,319 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $147.58 to $148.36. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 22:16 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,334 | $146.92 | $195,988.35 |
DisclosureSEC source: 0001567619-22-000622 · doc1.xml · nonDerivative · entry 4 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,819 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $146.54 to $147.45. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 22:16 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 4,083 | $145.96 | $595,936.71 |
DisclosureSEC source: 0001567619-22-000622 · doc1.xml · nonDerivative · entry 3 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,153 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $145.54 to $146.48. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 22:16 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,583 | $145.16 | $520,115.09 |
DisclosureSEC source: 0001567619-22-000622 · doc1.xml · nonDerivative · entry 2 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,236 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $144.54 to $145.53. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 22:16 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 10,000 | $5.04 | $50,400.00 |
DisclosureSEC source: 0001567619-22-000622 · doc1.xml · nonDerivative · entry 1 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,819 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:55 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001567619-21-021618 · doc1.xml · derivative · entry 12 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,159 Underlying: Class A Common Stock · 10,000 shares Expires 2028-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F11 · derivative.exercise_date: This option, originally for 600,000 shares, of which 239,841 shares have been exercised, vested as to 1/4th of the shares on October 8, 2019 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:55 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 100 | $155.55 | $15,555.00 |
DisclosureSEC source: 0001567619-21-021618 · doc1.xml · nonDerivative · entry 11 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,819 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:55 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 200 | $153.86 | $30,771.52 |
DisclosureSEC source: 0001567619-21-021618 · doc1.xml · nonDerivative · entry 10 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,919 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F10 · price: This transaction was executed in multiple trades at prices ranging from $153.58 to $154.135. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:55 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 300 | $151.80 | $45,539.01 |
DisclosureSEC source: 0001567619-21-021618 · doc1.xml · nonDerivative · entry 9 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,119 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F9 · price: This transaction was executed in multiple trades at prices ranging from $151.50 to $152.36. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:55 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 300 | $151.31 | $45,394.41 |
DisclosureSEC source: 0001567619-21-021618 · doc1.xml · nonDerivative · entry 8 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,419 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F8 · price: This transaction was executed in multiple trades at prices ranging from $151.26 to $151.38. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:55 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 500 | $150.71 | $75,357.00 |
DisclosureSEC source: 0001567619-21-021618 · doc1.xml · nonDerivative · entry 7 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,719 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $150.16 to $150.99. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:55 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 600 | $149.41 | $89,643.00 |
DisclosureSEC source: 0001567619-21-021618 · doc1.xml · nonDerivative · entry 6 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,219 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $149.14 to $150.12. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:55 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,302 | $148.48 | $193,320.96 |
DisclosureSEC source: 0001567619-21-021618 · doc1.xml · nonDerivative · entry 5 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,819 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $148.13 to $149.05. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:55 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,700 | $147.62 | $398,562.66 |
DisclosureSEC source: 0001567619-21-021618 · doc1.xml · nonDerivative · entry 4 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,121 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $147.06 to $148.03. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:55 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,536 | $146.49 | $225,014.32 |
DisclosureSEC source: 0001567619-21-021618 · doc1.xml · nonDerivative · entry 3 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,821 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $146.03 to $147.02. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:55 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,462 | $145.54 | $358,323.17 |
DisclosureSEC source: 0001567619-21-021618 · doc1.xml · nonDerivative · entry 2 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,357 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $145.01 to $145.99. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:55 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 10,000 | $5.04 | $50,400.00 |
DisclosureSEC source: 0001567619-21-021618 · doc1.xml · nonDerivative · entry 1 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,819 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| November 22, 2021 Filed Nov 25, 2021 02:10 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 281 | $148.38 | $41,695.09 |
DisclosureSEC source: 0001567619-21-021189 · doc1.xml · nonDerivative · entry 1 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,819 F1 · shares: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.